Literature DB >> 9261553

The expression of potency of neutralizing antibodies for interferons and other cytokines.

S E Grossberg1, Y Kawade.   

Abstract

The occurrence of antibody formation in patients administered biologically active human proteins as biotherapy for different diseases emphasizes the importance of establishing a common method of reporting neutralizing antibody levels for such cytokines. For quantitative neutralization bioassays, the preferred expression of the neutralizing potency of an antiserum is a titer, that is, the dilution of serum that reduces 10 Laboratory Units (LU)/ml of the cytokine to 1 Laboratory Unit/ml, the endpoint of most bioassays. This 10-to-1 LU/ml expression, which has been recommended by the World Health Organization for recording the results of interferon neutralization by the constant interferon method (with varying dilutions of serum) can also be used with the constant antibody method (with varying concentrations of interferon). For various reasons, interferon doses in International Units (IU)/ml should not be used for the neutralization test. Should the interferon concentration vary, intentionally or otherwise, from the intended dose of 10 LU/ml, a simple calculation allows expression of the neutralizing potency as the recommended reduction of 10-to-1 LU/ml as follows: the titer to be reported is the reciprocal of the antibody dilution (achieving the endpoint), multiplied by the interferon concentration (measured in that day's titration) minus one, divided by 9. This index of neutralization is the preferred method to represent the neutralizing potency of polyclonal and monoclonal antibodies and should make the results from different laboratories more readily interpretable and enable comparison.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9261553     DOI: 10.1007/bf02678220

Source DB:  PubMed          Journal:  Biotherapy        ISSN: 0921-299X


  6 in total

1.  Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.

Authors:  Anne H Cross; Jennifer L Stark; Joanne Lauber; Michael J Ramsbottom; Jeri-Anne Lyons
Journal:  J Neuroimmunol       Date:  2006-08-14       Impact factor: 3.478

2.  Quantification of the neutralization of cytokine biological activity by antibody: the ten-fold reduction bioassay of interleukin-6 as growth factor.

Authors:  Sidney E Grossberg; Monika Casey; Leslie D Grossberg
Journal:  J Interferon Cytokine Res       Date:  2009-08       Impact factor: 2.607

3.  Cellular targeting of engineered heterologous antigens is a determinant factor for bovine herpesvirus 4-based vaccine vector development.

Authors:  Gaetano Donofrio; Valentina Franceschi; Antonio Capocefalo; Simone Taddei; Chiara Sartori; Sabrina Bonomini; Sandro Cavirani; Clotilde S Cabassi; Cesidio F Flammini
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

4.  Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.

Authors:  Carolina Scagnolari; Milvia Casato; Francesca Bellomi; Francesca De Pisa; Ombretta Turriziani; Rossella Coviello; Maria Rosaria Pirro; Ferdinando Dianzani; Guido Antonelli
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

5.  MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity.

Authors:  Andrew Pachner; Kavitha Narayan; Nicholson Price; Marie Hurd; Donna Dail
Journal:  Mol Diagn       Date:  2003

6.  The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels.

Authors:  Sidney E Grossberg; Yoshimi Kawade; Leslie D Grossberg
Journal:  J Interferon Cytokine Res       Date:  2009-02       Impact factor: 2.607

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.